NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Altimmune, Inc. ALT
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$41,000
▲ 105.0% vs FY2024
EPS · FY25
$-1.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-50.6%
Net margin · FY25
-214861.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 41,000.00
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 214861 cents on every revenue dollar this year.
Per share
USD -1.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-50.6%
Return on equity, FY2025
ROE
Operating margin-230461.0%
Net margin-214861.0%
Return on assets-42.0%
Each USD of equity lost 51 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−65.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−65.3%
−34.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+39.2%
Change, 10 years—
The share count grew 39% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 279.9M
total assets, end of FY2025
Total assetsUSD 279.9M
EquityUSD 224.9M
CashUSD 43.8M
Gross debtUSD 34.3M
Net debtUSD -9.5M
Current ratio18.55×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
·
·
−0.0
·
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.00
−1.34
−1.66
−1.81
−2.35
−1.91
−1.60
−15.16
−118.91
−1.66
−0.05
−0.17
−0.23
−0.10
−0.08
−1.08
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−50.6
−59.9
−46.6
−44.1
−45.7
−36.1
−43.7
−89.3
−129.7
−29.4
−11.2
−77.7
−123.3
−35.7
−27.1
−285.4
Shares out B
0.11
0.07
0.07
0.05
0.04
0.04
0.02
0.01
0.00
0.01
0.06
0.06
0.05
0.05
0.05
0.05
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed